Valeritas Holdings Inc

Valeritas — Investor Presentation (August 2017)

24 slides from Valeritas's investor presentation, Aug 16, 2017

  1. Slide 1: Improving health and simplifying life for people with diabetes

    I m p r o v i n g h e a l t h a n d s i m p l i f y i n g l i f e f o r p e o p l e w i t h d i a b e t e s Investor Presentation NASDAQ: VLRX August 2017

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valeri

  3. Slide 3: Compelling Opportunity in Type 2 Diabetes Market

    3 • Significantly de-risked commercial stage company • 1H 2017: $9.4M revenue & 37.6% Gross Margin • > 12 million V-Go devices dispensed to patients • Targeting patients with Type 2 diabetes on insulin not at goal • ~4.5M in the U.S. on insulin that are not at their A1C goal • ~2M in the U.S. prescr

  4. Slide 4: The Valeritas Leadership Team

    4 John Timberlake President & Chief Executive Officer Board Member 26 / 10 Erick Lucera Chief Financial Officer 21 / 1 Matt Nguyen Chief Commercial Officer 21 / 10 Geoffrey Jenkins EVP Manufacturing, Operations, R&D 35 / 7 The Valeritas Leadership Team Proven Track Record of Success in Diabetes and

  5. Slide 5: The 4.5 Million Patients V-Go Can Benefit Represent a $16.5 Billion Market

    5 1. Based on V-Go® Wholesale Acquisition Price (WAC) of $306.70 per month x 12 months x 4.5M Patients with Type 2 Diabetes on Insulin not at goal. WAC price is the gross price sold to wholesalers, and does not take into account fees, discount and rebates charged to the company. 2. Holman RR et al.

  6. Slide 6: Non-adherence to Insulin is Associated with Poor Glycemic Control

    6 Non-adherence to Insulin is Associated with Poor Glycemic Control1 1. Donnelly L et al. Q J Medicine 2007:100;345-350. 2. Peyrot M et al. Diabetes Care 2010:33;240-245. 3. Peyrot M et al. Diabet Med. 2012:May;29(5): 682-689. 4. Yavuz D et al. Patient Preference and Adherence. 2015:9; 225-231. 5. D

  7. Slide 7: V-Go Wearable Insulin Delivery device: The Ideal Insulin Delivery Device for Type 2 Diabetes

    7 V-Go® Wearable Insulin Delivery device: The Ideal Insulin Delivery Device For Patients with Type 2 Diabetes • Only FDA-cleared single-use, fully disposable insulin delivery device with basal (background) and bolus (meal time) capability commercially available on the market in the US • Specifically

  8. Slide 8: V-Go Addresses Physicians' Greatest Concerns Regarding Challenges Patients Face on MDI

    8 V-Go® Addresses Physicians’ Greatest Concerns Regarding Challenges Patients with T2DM Face on MDI Based on market research conducted in October, 2016, n=102, Doctors ranked their Top 5 Challenges and separately the Greatest Benefits from V-Go Highest Rated Benefits from V-Go Greatest Challenges th

  9. Slide 9: V-Go Patient Feedback is Very Strong

    9 V-Go® Patient Feedback is Very Strong Extremely Satisfied = 38% Very Satisfied= 35% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=5% >90% of Patients are Satisfied with the Ease of Using V-Go Extremely Satisfied = 39% Very Satisfied= 32% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=6%

  10. Slide 10: Patients on V-Go See Improved Control, Positive Experience and High Compliance

    10 Patients on V-Go® See Improved Control, Have a Positive Experience and Achieve High Compliance 53% 36% 7% 3% 1% Very positive Positive Neutral Negative ~ 90% of V-Go Users have a Very positive/Positive Impression of V-Go* 0% 10% 20% 30% 40% 50% Greatly improved Slightly improved Remained the same

  11. Slide 11: Strong and Extensive Data Supports Broad Adoption of V-Go

    11 1. Rosenfeld CR, et al. Endocr Pract. 2012; 18 (5):660-667. 2. Grunberger, G, et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 985-P. 3. Omer, A. et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 980-P. 4. La

  12. Slide 12: Patients Switched to V-Go Significantly Lowered their A1C with ~55 Units/Day

    12 119 U7 (300) 99 U2 (310)* 84 U4 (NR) 76 U5 (NR) 62 U1 (NR) 67 U 3 (200) 49 U6 (86) 74 U8 (140) V-Go has consistently shown significant improvements in A1C using less insulin Mean and (Maximum) Total Insulin Doses in Units per Day Before V-Go From Multiple Studies 1. Grunberger G, et al. Poster pr

  13. Slide 13: V-Go Improved A1C Control Regardless of Baseline Insulin Dosing

    13 V-Go® Improved A1C Control Regardless of Baseline Insulin Dosing -1.5* -1.7* Cha n ge in A1 C < 100 U/day at Baseline ≥ 100 U/day at Baseline Baseline 9.3% Baseline 9.5% 62 143 54† 67* In su lin TD D (U/d ay ) Baseline Baseline On-V-Go On V-Go < 100 U/day at Baseline ≥ 100 U/day at Baseline After

  14. Slide 14: Prospective Study Demonstrated V-Go Improved A1C with Less Insulin

    14 Prospective Study Conducted by Healthcore Inc.(1) Demonstrated V-Go® Improved A1C with Less Insulin V-Go n=169 STO n=246 -0.95* -0.46* C ha n ge in A1 C *Significant compared to baseline, Significant between groups Baseline A1C (%): V-Go 9.88 and STO 9.34 Baseline total daily insulin dose (u/da

  15. Slide 15: Established Reimbursement: V-Go is Cost-effective for both Payors & Patients

    15 Established Reimbursement V-Go® is Cost-effective for both Payors & Patients V-Go® Therapy Basal/Bolus Pen Therapy Neutral Cost to Payors (~$17/day) between Regimens* *What a Payor Pays (Net of Rebates & Co-pays when V-Go Contracted in Preferred Position) $31 co-pay $31 co-pay $11 co-pay $31 co-p

  16. Slide 16: Current Sales & Marketing Model

    16 Higher Touch & Service S&M Model Target High Insulin Volume Prescribers High Frequency of Office Contact Greater Support for Prescriber & Patient Execute Multi- channel Marketing Activate Patients to Seek & Ask for V-Go Current Sales & Marketing Model Focused, Integrated and Capital Efficient wit

  17. Slide 17: Direct to Patient Activation Campaign

    17 Website Search Engine Optimization & Paid Search Social Media Direct to Patient Activation Campaign 90% of Patient’s who received Demo Kit have asked or plan to ask their Doctor about V-Go

  18. Slide 18: New Sales & Marketing Model is Resulting in Growth with Targeted Accounts

    18 New Sales & Marketing Model is Resulting in Growth with Targeted Accounts (Clinicians) • Non-disrupted Territories = same sales representative in the same territory > 6 months. • Disrupted Territories – same sales representative in same territory ≤ 6 months Launched New Strategy Expanded Sales Te

  19. Slide 19: First Quarter in which each Insulin Pump Company's Gross Margin achieved 35%

    19 First Quarter in which each Insulin Pump Company’s Gross Margin achieved 35% Gross Margins • V-Go® is a single-use, mechanical insulin delivery device and contains no electronics and no batteries, and is produced at high volume (each patient requires one V-Go per day) • Chart demonstrates the rel

  20. Slide 20: Valeritas: Financial Summary – June 30, 2017

    20 Valeritas: Financial Summary – June 30, 2017 *Balance sheet figures for the quarter ended June 30, 2017 are compared to figures as of December 31, 2016 Financial Summary ($ in millions) 2Q17 2Q16 Change Revenue $4.8 $4.9 -2.0% Gross Profit $1.8 $1.7 +4.5% Gross Margin 37.7% 35.3% +240 bp Cash Use

  21. Slide 21: V-Go Line Extension Products

    21 V-Go® Link2 V-Go® V-Go® Prefill2 • Prefilled insulin cartridge would eliminate filling step • No V-Go® EZ Fill refrigeration • Lower number of co-pays1 • Would provide revenue from insulin • Could expand target population • Extends patent life to 2032 1. Assumes V-Go devices and insulin cartridge

  22. Slide 22: Focused and Capital Efficient Growth Strategy

    22 Foundation: Capital-Efficient U.S. Sales & Market Strategy Advance V-Go® Next Generation Line Extensions Expand Sales Force in U.S. Launch V-Go® Link Focused and Capital Efficient Growth Strategy Scalable Business Model Short Term TIME Long Term Core Technology= h-patch platform OUS= Outside the

  23. Slide 23: Compelling Opportunity in Type 2 Diabetes Market

    23 • Significantly de-risked commercial stage company • 1H 2017: $9.4M revenue & 37.6% Gross Margin • Can achieve 50% Gross Margin on approximately $13M quarterly revenue • With current business plan and 45-50 reps, Company can generate free cash flow after two quarters with 50% gross margins • > 12

  24. Slide 24: Improving health and simplifying life for people with diabetes

    I m p r o v i n g h e a l t h a n d s i m p l i f y i n g l i f e f o r p e o p l e w i t h d i a b e t e s Investor Presentation NASDAQ: VLRX August 2017 ART-920 Rev F 08/2017

Valeritas Holdings — Investor Presentation (August 2017) on 6ix